Santarus "buy"

03/29/07 - Wedbush Morgan Securities

NEW YORK, March 29 (newratings.com) - Analysts at Wedbush Morgan reiterate their "buy" rating on Santarus (SNTS). The 12-month target price is set to $11.

In a research note published yesterday, the analysts mention that the total prescriptions for the company’s Zegerid drug for the week ended March 16 declined by 1.9% sequentially. The prescriptions for Zegerid 40mg capsule grew 2.3% during the week, which would continue to be the primary driver for growth in Zegerid’s total prescriptions, the analysts say. According to Wedbush Morgan, revenues from Zegerid in 1Q07 are expected to be in-line with the estimate.